Likun Gong

Dr. Likun Gong


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
LWLeyun Wu
Leyun Wu
LZLiping Zhou
Liping Zhou
MMMengxia Mo
Mengxia Mo
TLTingting Liu
Tingting Liu
CWChengkun Wu
Chengkun Wu
Zhijian XuZhijian Xu
Zhijian Xu

6 March 2020 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
SWShou-Yan Wu
Shou-Yan Wu
WWWen-Jie Wang
Wen-Jie Wang
JDJin-Hui Dou
Jin-Hui Dou
LGLikun Gong
Likun Gong

30 July 2018 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
SWShou-Yan Wu
Shou-Yan Wu
SCShi-Chao Cui
Shi-Chao Cui
LWLe Wang
Le Wang
YZYi-Ting Zhang
Yi-Ting Zhang
XYXiao-Xia Yan
Xiao-Xia Yan
LGLikun Gong
Likun Gong
Cholestasis is a common feature of liver injury, which manifests as bile acid excretion and/or enterohepatic circulation disorders. However, very few effective therapies exist for cholestasis. Recently, 18β-Glycyrrhetinic acid (18b-GA), a major metabolic component of glycyrrhizin, which is the main ingredient of licorice, was reported to protect against alpha-naphthylisothiocyanate (ANIT)-induced cholestasis. However, its protective mechanism remains unclear. We hypothesized that 18b-GA may stimulate the signaling pathway of bile acid (BA) transportation in hepatocytes, resulting its hepatoprotective effect. According to the results, 18b-GA markedly attenuated ANIT-induced liver injury as indicated the hepatic plasma chemistry index and histopathology examination. In addition, the expression levels of nuclear factors, including Sirt1, FXR and Nrf2, and their target efflux transporters in the liver, which mainly mediate bile acid homeostasis in hepatocytes, significantly increased. Furthermore, we first revealed that 18b-GA treatment significantly activated FXR, and which can be significantly reduced by EX-527 (a potent and selective Sirt1 inhibitor), indicating that 18b-GA activates FXR through Sirt1. Taken together, 18b-GA confers hepatoprotection against ANIT-induced cholestasis by activating FXR through Sirt1, which promotes gene expression of the efflux transporter, and consequently attenuates dysregulation of bile acid homeostasis in hepatocyte compartments.

29 July 2013 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
XQXin-Ming Qi
Xin-Ming Qi
LMLing-Ling Miao
Ling-Ling Miao
YCYan Cai
Yan Cai
LGLikun Gong
Likun Gong
JRJin Ren
Jin Ren

15 November 2018 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
YZYi-Ting Zhang
Yi-Ting Zhang
YYYu-Qi Yu
Yu-Qi Yu
XYXiao-Xia Yan
Xiao-Xia Yan
WWWen-Jie Wang
Wen-Jie Wang
XTXiao-Ting Tian
Xiao-Ting Tian
GPGuoyu Pan
Guoyu Pan

24 September 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Qiuping QinQiuping Qin
Qiuping Qin
LGLikun Gong
Likun Gong
Antibody–drug conjugates (ADCs) are a new class of biotherapeutics, consisting of a cytotoxic payload covalently bound to an antibody by a linker. Ligand-binding assay (LBA) and liquid chromatography-mass spectrometry (LC-MS) are the favored techniques for the analysis of ADCs in biomatrices. The goal of our review is to provide current strategies related to a series of bioanalytical assays for pharmacokinetics (PK) and anti-drug antibody (ADA) assessments. Furthermore, the strengths and limitations of LBA and LC-MS platforms are compared. Finally, potential factors that affect the performance of the developed assays are also provided. It is hoped that the review can provide valuable insights to bioanalytical scientists on the use of an integrated analytical strategy involving LBA and LC–MS for the bioanalysis of ADCs and related immunogenicity evaluation.